The project of experimental testing of the hypothesis regarding the effect of sodium phenylbutyrate for reducing dopamine depletion in the brain in Lesch-Nyhan syndrome using new personalized genetic HPRT1-deficient mouse as a pharmacological model
HPRT1 gene encoding the purine recycling enzyme hypoxanthine-guanine phosphoribosyltransferase (HPTR), the prevalence is approximately 1:380000. The disease manifests during the first year of life and is characterized

